| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Advances in Brief |
Institut National de la Santé et de la Recherche Médicale U-456, Detoxication and Tissue Repair Unit, Université de Rennes I, 35043 Rennes, France [O. M., N. T., D. L., J-P. C., B. C.]; Collagen Research Unit, Department of Medical Biochemistry, University of Oulu, 90220 Oulu, Finland [M. R., T. P.]; Service dAnatomie Pathologique B, Hôpital Pontchaillou, 35033 Rennes, France [B. T.]; and Service dAnatomie Pathologique, Université de Bordeaux 2, 33076 Bordeaux, France [P. B-S.]
Endostatin inhibits angiogenesis and tumor growth in mice. The role of
its endogenous precursor collagen XVIII in human cancer is unknown. In
normal tissues, two variants of collagen XVIII, namely, the
short and long forms regulate tissue specificity, the long form
being almost exclusively expressed by hepatocytes in the liver. We
analyzed RNA arrays from 57 hepatocellular carcinomas (HCCs) with
common and variant-specific probes and investigated the relationships
between collagen XVIII expression and angiogenesis by measuring the
CD34-positive microvessel density. Low collagen XVIII expression by
tumor hepatocytes was associated with large tumor size
(r, -0.63; P < 0.001)
and replacement of trabeculae with pseudoglandular-solid architecture
(
2, 28; P < 0.001), which
indicate tumor progression. Tumors expressing the highest collagen
XVIII levels were smaller and had lower microvessel density
(P = 0.01) than those expressing moderate
levels; and HCCs with the lowest collagen XVIII levels approached a
plateau of microvessel density, which indicated that a decrease in
collagen XVIII expression is associated with angiogenesis in primary
liver cancer. HCCs recurring within 2 years of resection showed
2.2-fold lower collagen XVIII mRNA than nonrecurring ones
(P = 0.02). The findings relied on the
hepatocyte-specific long form. Thus, the endogenous expression of the
endostatin precursor decreases along with tumor progression in
HCCs.
This article has been cited by other articles:
![]() |
Y. Ohta, R. Waseda, H. Minato, N. Endo, Y. Shimizu, I. Matsumoto, and G. Watanabe Surgical Results in T2N0M0 Nonsmall Cell Lung Cancer Patients With Large Tumors 5 cm or Greater in Diameter: What Regulates Outcome? Ann. Thorac. Surg., October 1, 2006; 82(4): 1180 - 1184. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Iizasa, H. Chang, M. Suzuki, M. Otsuji, S. Yokoi, M. Chiyo, S. Motohashi, K. Yasufuku, Y. Sekine, A. Iyoda, et al. Overexpression of Collagen XVIII Is Associated with Poor Outcome and Elevated Levels of Circulating Serum Endostatin in Non-Small Cell Lung Cancer Clin. Cancer Res., August 15, 2004; 10(16): 5361 - 5366. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Miosge, T. Simniok, P. Sprysch, and R. Herken The Collagen Type XVIII Endostatin Domain Is Co-localized with Perlecan in Basement Membranes In Vivo J. Histochem. Cytochem., March 1, 2003; 51(3): 285 - 296. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Iughetti, O. Suzuki, P. H. C. Godoi, V. A. Ferreira Alves, A. L. Sertie, T. Zorick, F. Soares, A. Camargo, E. S. Moreira, C. di Loreto, et al. A Polymorphism in Endostatin, an Angiogenesis Inhibitor, Predisposes for the Development of Prostatic Adenocarcinoma Cancer Res., October 1, 2001; 61(20): 7375 - 7378. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |